{
  "name": "ICH Q3B official document labels and regional qualifications",
  "description": "Original cross-authority compilation of FDA, EMA and TGA presentations of ICH Q3B. Each row combines the authority, document label and the implementation qualification stated in its official guidance or listing. This compares document presentation, not legal equivalence or review timelines.",
  "page": "https://casrai.org/guides/ich-q3b",
  "publisher": "CASRAI",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "dateModified": "2026-11-18T12:00:00Z",
  "temporalCoverage": null,
  "spatialCoverage": null,
  "columns": [
    {
      "name": "Authority",
      "unit": "",
      "description": ""
    },
    {
      "name": "Official presentation",
      "unit": "",
      "description": ""
    },
    {
      "name": "Stated qualification",
      "unit": "",
      "description": ""
    },
    {
      "name": "Source location",
      "unit": "",
      "description": ""
    }
  ],
  "rows": [
    {
      "Authority": "FDA",
      "Official presentation": "Q3B(R2) Impurities in New Drug Products, Revision 3",
      "Stated qualification": "Nonbinding recommendations; an alternative approach can satisfy applicable statutes and regulations. Revision 3 corrects the cover-page date, with other information unchanged.",
      "Source location": "FDA guidance: opening disclaimer and title-page footnote"
    },
    {
      "Authority": "EMA",
      "Official presentation": "ICH Q3B(R2), Step 5; CPMP/ICH/2738/99",
      "Stated qualification": "Listed as the current effective version for impurities in new drug products in registration applications.",
      "Source location": "EMA Q3B scientific-guideline listing"
    },
    {
      "Authority": "TGA",
      "Official presentation": "Adopted ICH Q3B(R2); CPMP/ICH/2738/99",
      "Stated qualification": "TGA annotations are nil. EU legislation referenced in adopted EU guidelines does not apply to TGA evaluation of medicines.",
      "Source location": "TGA Q3B adoption page: About this guideline"
    }
  ],
  "sources": [
    {
      "title": "FDA Q3B(R2) guidance, Revision 3",
      "url": "https://www.hhs.gov/guidance/sites/default/files/hhs-guidance-documents/FDA/7385fnl_ICH-Q3B%28R2%29_Rev.-3.pdf",
      "accessed": "2026-11-15"
    },
    {
      "title": "EMA Q3B(R2) scientific guideline listing",
      "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q3b-r2-impurities-new-drug-products",
      "accessed": "2026-11-15"
    },
    {
      "title": "TGA adoption of ICH Q3B(R2)",
      "url": "https://www.tga.gov.au/resources/resources/international-scientific-guidelines-adopted-australia/ich-topic-q-3-b-r2-impurities-new-drug-products",
      "accessed": "2026-11-15"
    }
  ]
}